BioSpace News Archive

IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., intends to raise €1,450,000,000 in gross proceeds through an offering of senior notes due 2026 and senior notes due 2029.

Lexaria Bioscience’s drug delivery technology, DehydraTECHTM improves the “bioavailability” of pharmaceutical ingredients.

Teleflex Incorporated, has been recognized as part of Forbes’ list of America’s Best Employers 2021.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the BIO CEO & Digital Conference, available online February 16-18, 2021.

Sio Gene Therapies Inc., a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021.

Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that it plans to release fourth quarter and fiscal year 2020 financial and operating results, and certain guidance for the first quarter and full year 2021, prior to market open on Tuesday, March 2, 2021.

CVS Health Corporation announced operating results for the three months and year ended December 31, 2020.

AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal diseases, announced that James Sapirstein, Chief Executive Officer, will present at The Microcap Rodeo Winter Wonderland Conference taking place virtually from February 16-19, 2021.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it will report its financial results for fiscal year 2020 on Monday, March 1, 2021 before the opening of the U.S. financial markets.

Clearside Biomedical, Inc. announced that David M. Brown, M.D. delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Bascom Palmer Eye Institute on February 12 & 13, 2021.